Skip to main content
Genmab logo

Genmab — Investor Relations & Filings

Ticker · GMAB ISIN · DK0010272202 LEI · 529900MTJPDPE4MHJ122 CO Manufacturing
Open in API
Filings indexed 2,815 across all filing types
Latest filing 2024-09-10 Share Issue/Capital Cha…
Country DK Denmark
Listing CO GMAB

About Genmab

https://www.genmab.com/

Genmab is an international biotechnology company that specializes in the creation, development, and commercialization of differentiated antibody therapeutics. The company focuses on transforming the treatment of cancer and other serious diseases. By utilizing proprietary antibody technology platforms and scientific expertise, Genmab develops a pipeline of innovative medicines. Its activities span from discovery and research through clinical development to deliver novel therapies to patients.

Recent filings

Filing Released Lang Actions
Share Issue/Capital Change 2024
Share Issue/Capital Change Classification · 1% confidence The document is a 'Company Announcement' from Genmab A/S detailing a 'Capital Increase in Genmab as a Result of Employee Warrant Exercise'. This announcement explicitly states the number of new shares issued, the subscription prices, the total proceeds, and the resulting change in the total nominal share capital. This content directly relates to changes in the company's capital structure and share count, fitting the definition of 'Capital/Financing Update' (CAP). Although it involves shares, it is not a report of the company buying back its own shares (POS), but rather an issuance due to warrant exercise, which is a financing/capital structure event. The document is short and appears to be the primary announcement, not just a notice of a larger report, thus RPA/RNS is less specific than CAP.
2024-09-10 English
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Share Issue/Capital Change Classification · 1% confidence The document is a formal company announcement from Genmab regarding an increase in share capital resulting from the exercise of employee warrants. It details the number of shares issued, the subscription prices, the impact on total share capital, and the regulatory compliance with the Danish Capital Markets Act. This fits the definition of a 'Share Issue/Capital Change' (SHA) announcement.
2024-09-10 English
6-K
Foreign Filer Report
2024-08-21 English
Legal Proceedings Report 2024
Legal Proceedings Report Classification · 1% confidence The document is titled "Company Announcement" and dated August 19, 2024. It announces that the European Commission (EC) has granted conditional marketing authorization for TEPKINLY® (epcoritamab) for treating relapsed or refractory follicular lymphoma (FL) and DLBCL. The text details the clinical trial data (EPCORE® NHL-1) supporting this approval, outlines the indications, and provides Important Safety Information (ISI) regarding CRS, ICANS, infections, TLS, and tumor flare. This content structure—an announcement of a regulatory decision supported by clinical data and safety warnings—is characteristic of a press release or an official company announcement regarding a significant regulatory event, rather than a comprehensive periodic report (like 10-K or IR) or a transcript. Since it is a formal announcement of a major regulatory milestone (marketing authorization) and not a general regulatory filing fallback (RNS) or a report itself, it best fits the category of a general corporate announcement, which often overlaps with Earnings Releases (ER) in format, but here it is specifically about a drug approval. Given the options, this is a significant corporate event announcement. It is not a standard Earnings Release (ER) which focuses on financial results, nor is it a proxy statement (DEF 14A) or a capital change (CAP). Since it is a major corporate news announcement regarding regulatory approval, and there isn't a specific 'Regulatory Approval Announcement' code, it falls closest to a general announcement. However, looking closely at the definitions, it is a formal announcement of a major corporate event (drug approval) that is not explicitly covered by other codes like DIV, CAP, or MANG. It is not a report itself (like 10-K or IR). It is most similar in nature to an Earnings Release (ER) in that it is an initial release of important, time-sensitive company news, but focused on regulatory/clinical success rather than financials. Given the context of a pharmaceutical company announcing a major marketing authorization, this is a high-impact corporate news release. If we must choose from the provided list, and recognizing it's not a financial report, a transcript, or a shareholder document, it functions as a high-level corporate update. Since it is not a report publication announcement (RPA) but the news itself, and it's not a standard financial release (ER), the most appropriate general category for significant, non-financial corporate news that doesn't fit elsewhere is often RNS, but RNS is defined as a 'fallback category for miscellaneous filings'. Given the high importance and structured nature, it strongly resembles an Earnings Release format but for regulatory news. I will classify it as a Regulatory Filing (RNS) as it is a formal announcement of a regulatory event, which is a common use case for RNS when a more specific code is unavailable, or as a general corporate announcement.
2024-08-19 English
TEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma
Regulatory Filings Classification · 1% confidence The document is a corporate press release announcing that Genmab A/S has received European Commission approval for a drug (TEPKINLY). It details the clinical trial results, the nature of the approval, and provides safety information. This is a standard corporate announcement regarding regulatory progress and product development, which falls under the 'Regulatory Filings' (RNS) category as it is a general corporate announcement that does not fit into more specific categories like financial reports, shareholder meetings, or dividend notices.
2024-08-19 Danish
6-K
Foreign Filer Report
2024-08-14 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.